Here’s a riddle to start your day:
What do acromegaly, Cushing’s disease, and epidermolysis bullosa have in common?
If you guessed that they all have treatments owned by a small pharma company in Europe, then you’d be right!
If you didn’t guess that, don’t worry. I didn’t know that either until I read this article.
Amryt Pharmaceuticals is a small company with some big names on it’s board, including Harry Stratford, who founded the rare-disease giant pharma company Shire.
For people living with epidermolysis bullosa (learn more about the condition here), Amyrt has some great news.
They’re raising $14 million in order to take a drug for epidermolysis bullosa into Phase 3 clinical trials.
If you’re familiar with epidermolysis bullosa, you know how the blistering thick wounds on the skin can make life hell. But Amyrt is hoping their new drug will help shorten the time it takes for those wounds to heal.
Unfortunately, when you’re living with a chronic illness and there aren’t many options to help treat it, waiting around for a Phase 3 trial can seem like forever.
However, the fact that big names in the pharma industry are paying attention to rare diseases like ours is huge!
Hopefully these deals will go through and we can get this Phase 3 trial on the road!
They say patience is a virtue…and when you have a chronic disease, you often need a lot of it.
